Full Breakdown
Boston Scientific to Acquire Nalu Medical for $533 Million
10/18/2025, 1:49:41 PM
Acquisition Overview
Boston Scientific Corporation has announced its intent to acquire Nalu Medical, a medical technology company specializing in chronic pain management, for approximately $533 million in cash. This acquisition is expected to be finalized in the first half of 2026, pending customary regulatory approvals. Boston Scientific has been a strategic investor in Nalu Medical since 2017, and this move aims to enhance its neuromodulation portfolio, particularly in the area of peripheral nerve stimulation (PNS).
Nalu Medical's Technology
Founded in 2014 and based in Carlsbad, California, Nalu Medical has developed the Nalu Neurostimulation System, which utilizes mild electrical impulses to interrupt pain signals before they reach the brain. The system features a miniaturized, battery-free implantable pulse generator that is powered wirelessly by an external therapy disc and can be controlled via a smartphone app. The device received U.S. Food and Drug Administration (FDA) clearance for PNS in 2019 and has shown promising clinical results, with 87% of participants in the COMFORT trial reporting over a 50% reduction in pain at 12 months.
Financial Implications
Boston Scientific anticipates that Nalu Medical will generate over $60 million in sales in 2025, with projected year-over-year growth exceeding 25% in 2026. The acquisition is expected to have an immaterial impact on Boston Scientific's adjusted earnings per share (EPS) in 2026, becoming slightly accretive in 2027 and increasingly beneficial thereafter. However, on a Generally Accepted Accounting Principles (GAAP) basis, the acquisition may initially be dilutive due to amortization expenses and other acquisition-related costs.
Strategic Importance
This acquisition is part of Boston Scientific's broader strategy to expand its offerings in the global pain management market, which is increasingly leaning towards non-opioid solutions. The addition of Nalu Medical's technology complements Boston Scientific's existing therapies, including spinal cord stimulation and radiofrequency ablation, thereby enabling the company to provide a wider range of advanced pain relief options.
Criticism & Opposition
While the acquisition is largely viewed positively within the industry, some analysts have expressed caution regarding the competitive landscape. RBC Capital Markets analyst Shagun Singh noted that while Nalu's system is robust in the PNS market, Boston Scientific already has established offerings in spinal cord stimulation, which may limit potential share gains in that segment.
Verbatim Quotes
“Peripheral nerve stimulation is an exciting field with a significant unmet patient need. Adding the highly differentiated Nalu Medical technology complements our existing therapies—including spinal cord stimulation, basivertebral nerve ablation and radiofrequency ablation—enabling us to deliver advanced pain relief options to a wider variety of patient populations.” — Jim Cassidy, President, Neuromodulation, Boston Scientific
What's Next
As the acquisition progresses, Boston Scientific will focus on integrating Nalu Medical's technology into its existing portfolio. The company is expected to continue pursuing additional acquisitions to bolster its position in the neuromodulation market, which is projected to grow at a compound annual growth rate (CAGR) of 6.8% to reach a valuation of $12.3 billion by 2034.
